DA
ESPR

DCF Advisers’s Esperion Therapeutics ESPR Stock Holding History

DCF Advisers’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-17,286
Closed -$485K – 101
2021
Q1 		$485K Sell
17,286
-21,214
-55% -$626K 0.21% 79
2020
Q4 		$1M Sell
38,500
-18,000
-32% -$539K 0.41% 47
2020
Q3 		$2.1M Buy
56,500
+8,000
+16% +$317K 1.07% 30
2020
Q2 		$2.49M Buy
48,500
+26,500
+120% +$1.11M 1.39% 22
2020
Q1 		$694K Buy
22,000
+7,000
+47% +$369K 0.45% 40
2019
Q4 		$894K Buy
+15,000
New +$674K 0.57% 41

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

DCF Advisers's ESPR Position: Q2 2021 in Review

DCF Advisers sold out of Esperion Therapeutics (ESPR) in Q2 2021, closing a stake of 17,286 shares — an estimated $485K sold.

DCF Advisers first reported a position in ESPR in Q4 2019 and held it in 6 quarters. The position peaked at $2.49M in Q2 2020. 142 funds tracked by Wall St. Rank hold ESPR as of Q2 2021.

  • DCF Advisers reported no remaining Esperion Therapeutics position as of Q2 2021 after selling out during the quarter.
  • DCF Advisers sold 17,286 Esperion Therapeutics shares in Q2 2021, an estimated $485K.
  • DCF Advisers first reported a position in Esperion Therapeutics in Q4 2019 and held it in 6 quarters.
  • DCF Advisers's Esperion Therapeutics position peaked at $2.49M in Q2 2020.
  • 142 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2021.

Based on DCF Advisers's 13F filing for Q2 2021, filed 13 Aug 2021.